注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
德琪醫藥有限公司是一家專注於創新抗腫瘤藥物的亞太地區臨床階段生物製藥公司。該公司主要從事生物科技產品的發現、開發、生產及商業化。該公司的主要產品包括用於治療復發╱難治性多發性骨髓瘤、復發╱難治性瀰漫大B細胞淋巴瘤和非小細胞肺癌的ATG-010(selinexor)及用於治療肝細胞癌和非小細胞肺癌等多種適應症的ATG-008(onatasertib)。該公司主要在亞太地區開展業務。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jay Mei | 55 | 2018 | Founder, Chairman & CEO |
Donald Andrew Lung | 40 | 2020 | CFO & Executive Director |
Shaji K. Kumar | - | - | Member of Scientific Advisory Board |
Sheng Tang | 38 | 2020 | Independent Non-Executive Director |
Joseph Camardo | 70 | - | Member of Scientific Advisory Board |
Jing Qian | 46 | 2020 | Independent Non-Executive Director |
John F. Chin | 56 | 2020 | Executive Director & Chief Business Officer |
Robert Gale | - | - | Member of Scientific Advisory Board |
Kan Chen | 41 | 2021 | Non-Executive Director |
Timothy M. Block | 68 | - | Member of Scientific Advisory Board |
Jeffrey Barrett | - | - | Member of Scientific Advisory Board |
Wei-Li Zhao | - | - | Member of Scientific Advisory Board |
Ricky Johnstone | - | - | Member of Scientific Advisory Board |
Florence Houn | - | - | Member of the Scientific Advisory Board |
Rafael Fonseca | 56 | 2023 | Independent Non-Executive Director |
Jayesh Desai | - | 2023 | Member of Scientific Advisory Board |
Yi-Long Wu | - | 2023 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核